MedPath

Efficacy of the Malva sylvestris & Alcea digitata &Plantago Psyllium on prevention of radiation induced xerostomia in head and neck cancer patients

Phase 2
Conditions
Radiation induced xerostomia.
Dry mouth, unspecified
Registration Number
IRCT2015091015860N3
Lead Sponsor
Tehran University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
44
Inclusion Criteria

Inclusion criteria include:
1. head and neck cancer patients who candidate for radiation therapy
2. minimum age of 17 and maximum age of 65 years old
3. having Good Performance status according with ECOG questionnaire criteria
4. having at least 4 regions of mucositis (based on a measure of mucositis) in the field of radiation therapy
5. physically and mentally able to fill out a questionnaire
6. willingness to participate in the study
7. survival more than one year according to the oncologist or treatment team.
Exclusion criteria:The use of alcohol, medicines which affecting the salivary glands such as: anti-depression, opioids, anti-hypertensive, antihistamines, diuretics, types of mouthwash and artificial saliva and smoking during the study; Receiving radiation therapy and chemotherapy in the mouth and oropharynx in the six months ago; The history of connective tissue diseases such as Sjogren's syndrome, rheumatoid arthritis, lupus, liver and kidney disease, major depression, diseases involving salivary glands, diabetes, chronic diseases such as diarrhea cause dehydration, immune suppression disorders, myelosuppression, disorders which causing frequent aphthous stomatitis; Sudden changes in the patient's condition or disease in which changing the predicted radiation procedure for patient before getting to dose of 50 Gy; Grade 3 & 4 mucositis; Candidiasis and oral herpes infection; Failure/ need parenteral nutrition (TPN) or hospitalization; Unwillingness to continue participation in the study

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Xerostomia. Timepoint: Before interventin and 2 and 6 weeks after finishing radiation therapy. Method of measurement: VAS scale (determined by Question from patient) & Xerostomia Grade (determined by clinical examination).
Secondary Outcome Measures
NameTimeMethod
Quality of life. Timepoint: Before interventin and 2 and 6 weeks after finishing radiation therapy. Method of measurement: EORTC questionnaire.
© Copyright 2025. All Rights Reserved by MedPath